Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sipuleucel-T + docetaxel
- Development stage
- Unknown
- Lead developer
- Dendreon
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Small Molecules, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
Sipuleucel-T + docetaxel is a sequential combination therapy being evaluated for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Sipuleucel-T (Provenge) is an autologous cellular immunotherapy, the first FDA-approved therapeutic cancer vaccine, which involves harvesting a patient's peripheral blood mononuclear cells and activating them ex vivo with a fusion protein (PA2024) consisting of prostatic acid phosphatase (PAP) and granulocyte-macrophage colony-stimulating factor (GM-CSF). Docetaxel is a taxane chemotherapy agent that promotes microtubule assembly and inhibits depolymerization, leading to cell cycle arrest. This specific regimen, studied by The University of Texas Health Science Center at Houston, investigates whether the immune activation provided by sipuleucel-T can be followed by docetaxel to improve clinical outcomes and correlate immunological biomarkers with tumor response.
- Brand names
- ProvengeTaxotere
- Other names
- sipuleucel-T followed by docetaxelProvenge followed by docetaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))PAP (Prostatic acid phosphatase)
Beyond the preview
Go deeper on sipuleucel-T + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sipuleucel-T + docetaxel.